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15-PGDHHigh-mobility group box 1 (HMGB1) enhances inﬂammatory reactions by potentiating the activity of pro-
inﬂammatory mediators and suppressing the phagocytosis of apoptotic neutrophils. However, the effects
of HMGB1 on phagocytosis induced by pro-resolving mediators, such as resolvins, have not been studied up
until this point. In this study, we investigated the effects and underlying mechanism of HMGB1 on resolvin
D1-induced phagocytosis ofMDA-MB-231 cells,whichwere selected as amodel systembased on their phagocyt-
ic capability and ease of transfecting themwith a plasmid or siRNA in several cancer cell lines. Thenwe conﬁrmed
effects of HMGB1 in THP-1 cells.
Resolvin D1 (RvD1) enhanced phagocytosis inMDA-MB-231 and THP-1 cells. HMGB1 suppressed RvD1-induced
phagocytosis in MDA-MB.231 and THP-1 cells. HMGB1 dose-dependently induced the expression of 15-
hydroxyprostaglandin dehydrogenase (15-PGDH), the inactivating enzyme in pro-resolving lipid mediators
such as RvE1 and RvD1. Involvement of 15-PGDH in-HMGB-1-induced suppression of phagocytosis was exam-
ined using siRNA of 15-PGDH or 15-PGDH inhibitor, TD23. Surprisingly, the silencing of 15-PGDH increased
phagocytotic activity of MDA-MB-231 cells. TD23 also enhanced phagocytosis of MDA-MB-231 and THP-1 cells.
In conclusion, the release of HMGB1 during the inﬂammatory phase induces 15-PGDH expression, which
suppresses the phagocytotic activity of macrophages. These processes might be involved in the mechanism
that blocks the resolution of inﬂammation, thereby allowing acute inﬂammation to progress to chronic
inﬂammation.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Inﬂammation is an essential protective mechanism that removes
harmful stimuli, as microorganisms and damaged tissues [1]. Successful
clearance of infectious microbes and damaged tissue followed by the
disappearance of the inﬂammatory exudate is a process known as reso-
lution [2]. However, nonresolving inﬂammation is a major driver of
severe diseases, including cancer and autoimmune diseases [3].
In order to achieve normal resolution of inﬂammation, the body
employs a substantial number of lipid mediators (LMs), which are de-
rived from both ω-6 polyunsaturated fatty acid and the ω-3 polyunsat-
urated fatty acids (PUFAs) EPA and DHA, including lipoxins (LXs),
prostaglandins (PGs), Protectins (Ps), resolvins (Rvs), to name a few
[4]. These mediators display potent anti-inﬂammatory, pro-resolving,
immunoregulatory and neuroprotective properties through multipleactions, such as arresting the recruitment of polymorphonuclear leuko-
cytes (PMN), blocking leukotrienes (LTs) and PGs, and reducing cyto-
kine release and the recruitment of monocytes [5,6]. Phagocytic
removal of apoptotic leukocytes is a prerequisite for the restoration of
normal tissue function, and plays a critical role in the resolution of
inﬂammation [2,7,8]. In this process, Rvs, for example, promote resolv-
ing phagocytosis [5]. RvE1 and PD1 in nanogram ranges promote
phagocyte removal during acute inﬂammation, via regulation of leuko-
cyte inﬁltration, increasing macrophage ingestion of apoptotic PMNs
in vivo and in vitro, and enhancing the appearance of phagocytes carry-
ing engulfed zymosan in lymph nodes and spleen [9]. RvD1 enhanced
macrophage phagocytosis of zymosan and apoptotic PMNs, which in-
creased with overexpression of human ALX and GPR32 and decreased
with selective knockdown of these G-protein-coupled receptors [10].
In the inﬂammatory milieu, RvE1 mediates counter-regulatory actions
initiated via speciﬁc G protein-coupled receptors such as ChemR23 [11].
High-mobility group box 1 (HMGB1) is a nuclear non-histone
DNA-binding protein that binds to speciﬁc DNA targets. HMGB1 is
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necrotic and apoptotic cells in response to infection, injury, and inﬂam-
mation [12–15]. HMGB1 was released by cultured macrophages more
than 8 h after stimulation with endotoxin, TNF-α, or IL-1 and mice
showed increased serum levels of HMGB-1 between 8–32 h after endo-
toxin exposure [12]. Macrophages that ingest apoptotic cells begin to
secret HMGB1 [16]. Unlike in sepsis, HMGB1 levels are increased as
early as 1 h after ischemia/reperfusion injury and then increase in a
time-dependent manner for up to 24 h [17].
15-PGDH is an enzyme degrading several lipid mediators such as
PGE1, LxA4, RvD1, and RvE1 [18–21]. 15-PGDH decrease was reported
in lung, gastric, thyroid cancers [22–24]. Reduced expression of 15-
PGDH is observed in the systemic inﬂammatory response and inﬂam-
matory bowel disease [25,26]. The time course of 15-PGDH induction
by phorbol 12-myristate 13-acetate (PMA) was reported in U937 cells.
Maximum induction was observed at 24–36 h following the addition
of PMA [27]. This induction by PMA was inhibited by the concurrent
addition of dexamethasone [27].
We are interested in the reports that chronic inﬂammation might
be due to failure of resolution and antiresolution factormight be existed
to interfere the resolution response [28,29]. We speculated that antire-
solution factor might be delayed expression pattern in inﬂammation
and suppress efferocytosis [12,30]. Many recent reports have indicated
that HMGB1 enhances andmaintains inﬂammatory reactions by poten-
tiating the activity of pro-inﬂammatory mediators such as LPS and
cytokines, and by suppressing the phagocytosis of apoptotic neutrophils
[30–32]. However, no studies up to this point have focused on under-
standing the relationship betweenHMGB1 and pro-resolvingmediators
such as Rvs. We speculated that HMGB1 might block the action of pro-
resolving mediators.
In this study, we examine the effects and underlying mechanism
of HMGB1 on RvD1-induced phagocytosis in MDA-MB-231 cells
which were selected as model system based on their phagocytic capa-
bility and ease of transfecting them with a plasmid or siRNA in several
cancer cell lines [33–35]. We also conﬁrmed the effects of HMGB1 on
phagocytosis of THP-1 cells. We found that HMGB1 suppresses RvD1-
induced phagocytosis via induction of the RvD1 inactivation enzyme,
15-hydroxyprostaglandin dehydrogenase (15-PGDH) and 15-PGDH
is important in suppression of phagocytosis.
2. Materials and Methods
2.1. Chemical and reagents
RPMI-1640 medium, high-glucose Dulbecco's Modiﬁed Eagle Medi-
um (DMEM), fetal bovine serum (FBS), phosphate-buffered saline
(PBS), and antibiotics (penicillin and streptomycin) were purchased
from Welgene Inc. (Korea). Resolvin D1 was gained from Cayman
Chemical (Ann Arbor, MI). Recombinant protein HMGB1 and 15-
PGDH were obtained from R&D Systems (Minneapolis, MN). RvD1
was acquired from Cayman Chemical (Ann Arbor, MI). Anti-HMGB1 an-
tibody was obtained from Cell Signaling (Beverly, MA), anti-15-PGDH
antibody from Abcam (Cambridge, MA), and β-actin antibody from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Fluorescein isothiocya-
nate (FITC)-labeled zymosan was purchased from Invitrogen (Carlsbad,
CA). All of the other chemicals were of reagent grade.
2.2. Cell culture
The human cell lines THP-1, HT1080, and Jurkat human cell lines
were cultured in RPMI1640 medium and MDA-MB-231, MCF7, and
HaCaT human cell lines were high glucose DMEM. All cell lines were
cultured with 10% FBS and 1% antibiotics in a humidiﬁed CO2 incubator.
Human THP-1 cells differentiated into macrophage-like cells by treat-
ment with TPA (12-O-tetradecanoylphorbol-13-acetate).2.3. RNA preparation and polymerase chain reaction (PCR)
Total RNA was prepared using TRIzol® RNA Isolation Reagents
(Invitrogen) according to themanufacturer's instructions. Reverse tran-
scription was performed with a ﬁrst strand cDNA synthesis kit
(Promega, Madison, WI).
The reverse transcription PCR reaction was performed in the 96-Well
GeneAmp® PCR System 9700 (Applied Biosystems, Piscataway, NJ) using
AccuPower® HotStart PCR PreMix (Bioneer, Korea) with the appropriate
sense and antisense primers. The primer sequence was as follows: 15-
PGDH (F 5′-CCAATTTTGCCACAGCCACA-3′, R 5′-CTTCAAGCTGGGAGGT
CTGG-3′; 274 bp), HMGB1 (F 5′-AGCACCCAGATGCTTCAGTC-3′, R 5′-
CCTCTTGGGTGCATTGGGAT-3′; 203 bp), and β-actin (F 5′-TGAAGCT-
GAGGGAGCCACAGC-3′, R 5′-GGGTTCTCCCTGGGCACCAA-3′; 540 bp).
The reaction products were visualized by electrophoresis on a 1.2% aga-
rose gel (Invitrogen) under UV light illumination after staining with
SafePinky DNA Gel staining solution (GenDEPOT, Inc., Barker, TX).
Real-time quantitative PCR was performed with an iQ™ SYBR®
Green Supermix (Bio-Rad, Hercules, CA) with a CFX384 Real-Time PCR
(Bio-Rad). Real-time PCR for the relative quantiﬁcation of target gene
copy numbers in relation to GAPDH expression was conducted using
the following primers; 5′-CAGGTCCGGAAGGCAAAGAT-3′ (forward)
and 5′-GGGGAGGAAACTGTC AAGCC-3′ (reverse) for 15-PGDH, 5′-
CCTCAAGATCATCAGCAATG-3′ (forward) and 5′-
AGTCCTTCCACGATACCA-3′ (reverse) for GAPDH. Real-time PCR results
were expressed using the CFX Manager software (Bio-Rad) that mea-
sures ampliﬁcation of the target and the endogenous control in experi-
mental samples and in a reference sample. Measurements were
normalized using the endogenous control.
2.4. Western blot analysis
Cells were washed twice with ice-cold PBS and disrupted in RIPA
buffer with protease inhibitor cocktail and Xpert Phosphatase Inhibitor
Cocktail Solution (GenDEPOT, Inc.) on ice for 30 min. Cell lysates were
centrifuged at 15,000 rpm for 15min at 4 °C, and the resultant superna-
tants were subjected to Western blotting. The total protein concentra-
tion was quantiﬁed using the Coomassie (Bradford) Protein Assay Kit
(Thermo Fisher Scientiﬁc, Rockford, IL). Proteins were separated by
electrophoresis on a 12% sodium dodecyl sulfate polyacrylamide gel
(SDS-PAGE), afterwhich sampleswere transferred onto a polyvinylidene
diﬂuoride (PVDF) membrane. The membrane was treated with 5% skim
milk for 1 h and incubated overnight at 4 °C with the appropriate prima-
ry antibodies. After TBST washing, the membrane was incubated with
horseradish peroxidase (HRP)-conjugated secondary antibody (1:5000)
for 90 min at room temperature. The proteins were visualized with
PowerOpti-ECL detection reagent (Animal Genetics Inc., Korea) using
the ChemiDoc™ XRS+ System (Bio-Rad). Proteins in the cell superna-
tants were precipitated with MeOH/CHCL3 and resuspended in sample
buffer and separated by SDS-PAGE.
2.5. Gene silencing
HMGB-1 siRNA (sequence (I): 5′-AAGCACCCAGAUGCUUCAGU-3′,
(II):5′-CUGCGAAGCUGAAGGAAAA-3′) and 15-PGDH siRNA (sequence
(I): 5′-GCGGCAUCAUUAUCAAUAU-3′, (II): 5′-GCUGGUGCAUUGGAAU
CUU-3′) was purchased from Santa Cruz Biotechnology and ST Pharm
(Korea). Cells were transfected with siRNA using Lipofectamine™
2000 Transfection reagent (Invitrogen) following the manufacturer's
protocol. The ratio of siRNA versus Lipofectamine reagent was 1:1.15.
After 48 h of transfection, the cells were used in further experiments.
2.6. Phagocytosis assay
FITC-labeled zymosan A particles were pre-treated with opsonizing
reagent (Invitrogen) according to the manufacturer's instructions. To
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pre-exposed to RvD1 for 10 min at 37 °C, and stimulated with HMGB1.
After 30min of stimulation, FITC-zymosanparticleswere added and incu-
bated for 24 h. THP-1 cells were differentiated to human macrophage-
like cells by treatment of TPA (20 nM) for 48 h. And then cells were
pre-exposed to RvD1 for 10 min at 37 °C, and the cells were additionally
incubated with FITC-zymosan particles for 30min in a presence of RvD1.
Also, the cells were pre-stimulated with HMGB1 for 24 h and then ex-
posed to RvD1 and FITC-zymosan particles. After washing with PBS, the
cells were ﬁxed with 4% paraformaldehyde (PFA) for 15 min. To deter-
mine the number of ﬂuorescent-green particles, counts were conducted
in four randomly chosen ﬁelds under ×10 magniﬁcation (Leica,
Germany) or ﬂow cytometric analysis (FACSAria™ III, BD Biosciences,
San Jose, CA). FACSDiva software 6.1.3 used for data analysis. In MDA-
MB-231 cells, Number of ﬂuorescent particles was counted the ﬂuores-
cent particles in the image of ﬂuorescence microscope. In THP-1 macro-
phages, FITC-positive cells were calculated as the total number of cells
with at least two beads as a percentage of the total number of cells count-
ed from the image of ﬂuorescence microscope.
2.7. Enzyme-linked immunosorbent assay
Theproduction of TNF-α, IL-6, andTGF-βproteins in the supernatant
of the cultured cells was measured using ELISA kits (R&D Systems Inc.)
according to the manufacturer's instructions.
2.8. Enzyme assay
Substrate mixture containing RvD1 (50 μM) and NAD+ (1 mM,
Sigma) in 100 μL assay buffer (50 mM Tris, 0.1 mM Dithiothreitol
(DTT), pH 7.5) was incubated with recombinant 15-PGDH (0.1 μg) or
HMGB1 (10 or 100 ng, 30 min)-pretreated 15-PGDH. 15-PGDH activity
was monitored spectrophotometrically by the formation of NADH from
NAD+ for 45min at 37 °C (340 nm, SpectraMaxM3, Molecular Devices,
Sunnyvale, CA).
2.9. Identiﬁcation of Oxo-RvD1 by LC-MS
The sample preparation for analysis of RvD1 and RvD1 metabolites
were described in previous studies [18,36]. Brieﬂy, after reaction termi-
nated with addition of 200 μL of cold MeOH, the sample mixtures were
centrifugedwith 16,000 g at 4 °C in 15min. After addition of 1mLwater
to the supernatant and pH adjustment to 3.5 by 1 M HCl, the acidiﬁed
sampleswere extracted and puriﬁedwith C18 based solid phase extrac-
tion (SPE) method [36]. The ﬁnal product was analyzed by HPLC-PDA-
MS/MS system. Liquid chromatography were performed using Agilent
1290 UPLC system equipped with C18 based Brownlee SPP column
(2.7 μm, 2.1 mm × 75 mm, PerkinElmer, Branchburg, NJ, USA). The
isocratic mobile phase (methanol:water:acetic acid, 65:35:0.01, v/v/v)
was eluted at a 0.2 ml/min ﬂow rate and UV spectrum was acquired
by 1290 Inﬁnity Diode Array Detector (Agilent, CA, USA) before MS/
MS analysis. The MS/MS analysis were carried out using a 6460 triple
quadruple MS/MS system (Agilent, CA, USA) at negative mode. For
MS/MS scan, 100 to 400 m/z was set as scan rage and the 110 and 120
of fragment voltages were used for fragment ion scan of the 373 and
375 m/z, respectively. For multiple reaction monitoring (MRM), 10
and 13 eV were used for monitoring of 231 m/z from 373m/z of parent
ions (oxo-RvD1s) and 233 m/z for 375 m/z of parent ions (RvD1),
respectively.
2.10. Statistical analysis
The student's t-testwas used to determine the statistical signiﬁcance
of the differences between the experimental and control group values.
The data presented represent the mean ± standard deviation.3. Results
3.1. RvD1 enhanced phagocytosis of MDA-MB-231 cells
Usually, cells of hematopoietic origin, such as THP-1 cells or primary
macrophage cells, were used to evaluate the phagocytic capability but
transfecting themwith a plasmid or siRNAwas difﬁcult. So, we selected
MDA-MB-231 cancer cells since several researchers reported that these
cells have phagocytic capability [37,38]. We ﬁrst conﬁrmed the phago-
cytic activity of MDA-MB-231 cells and examined the effects of RvD1
on the phagocytic activity of MDA-MB-231 cancer cells (Figs. 1, 1S).
We found that RvD1 enhanced phagocytosis of MDA-MB-231 in time
dependentmanner (Fig. 1B). We also conﬁrmed that RvD1 dose depen-
dently enhanced phagocytosis of THP-1 cells (Fig. 1C). RvD1 enhanced
phagocytosis of raw264.7 and murine peritoneal macrophages (Fig. 2S).
3.2. HMGB1 suppressed the RvD1-enhanced phagocytosis
HMGB1 is known to suppress the phagocytosis of several cells,
including macrophages and neutrophils [30–32]. So we examined
whether HMGB1 suppressed the RvD1-induced phagocytosis of MDA-
MB-231 cells. HMGB1 suppressed the phagocytosis of MDA-MB-231
cells in the presence and absence of RvD1 (Fig. 2A). HMGB1 also sup-
pressed the RvD1-enhanced phagocytosis of THP-1 cells (Fig. 2B).
We also examined the effects of HMGB1 on the inﬂammatory cyto-
kines such as TNF-α, and IL-6 and anti-inﬂammatory cytokine, TGF-β1
in MDA-MB-231 cancer cells and THP-1 cells by ELISA. In THP-1 cells,
HMGB-1 induced expression of TNF-α and IL-6 (Fig. 3S). However,
TNF-α and IL-6 were not detected in MDA-MB-231 cells (data not
shown). HMGB-1 reduced expression of TGF-β1 in THP-1 and MDA-
MB-231 cells (Fig. 3S).
3.3. HMGB1 induced the expression of 15-PGDH
HMGB1 treatment suppressed RvD1-induced phagocytosis and
gene silencing of HMGB1 induced phagocytosis and that led us to inves-
tigate themechanism of HMGB1's suppression of RvD1-induced phago-
cytosis ofMDA-MB-231 cells.We initially speculated thatHMGB1might
inactivate RvD1. Therefore, we examined the effects of HMGB1 on the
RvD1-inactivating enzyme, 15-PGDH. HMGB1 dose-dependently in-
duced 15-PGDH mRNA expression (Fig. 3A). After treating cells with
HMGB1 for 24 h, the level of 15-PGDH was examined by Western blot
analysis. HMGB1 induced 15-PDGH protein expression in both MDA-
MB-231 and THP-1 cells (Fig. 3B). HMGB-1 induced 15-PGDH expres-
sion is also observed in various cells (Fig. 4S). Gene silencing of
HMGB1 reduced 15-PGDHexpression at themRNA (Fig. 3C) and protein
levels (Fig. 3D). We also conﬁrmed that HMGB-1 increased the activity
of 15-PGDH by measuring the NADH produced in enzyme reaction
(Fig. 5S). RvD1-derived oxoRvD1 was conﬁrmed in assay mixtures
containing RvD1, NAD+, and cell lysates from HMGB1-treated MDA-
MB-231 cells (Fig. 6S). These results indicate that HMGB1 induces ex-
pression and activity of 15-PGDH.
3.4. Involvement of 15-PGDH in phagocytosis of MDA-MB-231 cells
To investigate 15-PGDH's involvement in HMGB-1-suppressed
phagocytosis, we examined the effects of 15-PGDH gene silencing on
HMGB1-induced phagocytosis of MDA-MB-231 cells since THP-1 cells
have low efﬁciency of transfection and require additional differentiation
step induced by TPA. Gene silencing of 15-PGDH is conﬁrmed by
Western blot (Fig. 4A). HMGB1 in control-siRNA-transfected cells
suppressed RvD1-induced phagocytosis, whereas gene silencing of
15-PGDH increased phagocytosis, even without HMGB1 and RvD1
treatment (Fig. 4B, C). So, we also conﬁrmed the effects of 15-PGDH
on phagocytosis of MDA-MB-231 cells and THP-1 cells using TD23,
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pre-treated with RvD1 in a dose-dependent manner (for 10 min). And then the cells were incubated with zymosan particles conjugated with FITC (4.0 × 104 particles/μL) for 30 min.
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(Fig. 4D).
These results suggest that HMGB1 inhibits phagocytosis of MDA-
MB-231 cells through the regulation of 15-PGDH. 15-PGDH itself is
important in regulation of phagocytosis.
4. Discussion
In this study, we showed that HMGB1 inhibits RvD1-induced phago-
cytosis via the induction of 15-PGDH enzyme expression, which in-
activates PGE2, LxA4, RvD1 and RvE1 [18–21]. RvD1 is one of well-
characterized pro-resolving lipid mediators that induces efferocytosis
of macrophage during the resolution stage of inﬂammation [5,40,41].
It is known that pro-resolving lipid mediators, including RvD1, begin
to be synthesized in the early phase of inﬂammation, although they
did not induce resolution such as efferocytosis in the early phase [7].
Recent reports have revealed that HMGB1 plays an important role
in maintaining inﬂammation. It can be actively released from various
immune cells such as macrophages, monocytes, NK cells, dendritic
cells, and endothelial cells, as well as from necrotic cells [42–44]. The
most familiar HMGB1 mechanism for inﬂammation is the induction of
inﬂammatory cytokine release [45–47]. Recent studies have shown
that extra- or intracellular HMGB1 can inhibit the efferocytosis of
macrophages,which is an important process of inﬂammation resolution
[30–32].We hypothesized that some players that have an important role
in the maintenance of inﬂammation, and might act as antiresolution
factor and inhibit the efferocytosis induced by pro-resolving lipid
mediators such as RvD1 [28–30]. HMGB1 is the best candidate
since it suppressed efferocytosis [30,31]. Therefore, we examined
the effects of HMGB1 on RvD1-enhanced phagocytosis of MDA-MB-
231 cancer cells which were chosen as a model phagocytic cell sys-
tem because they were easy to handle and transfect. MDA-MB-231
cancer cells are known to have phagocytic activity [33–35], and
RvD1 enhanced the phagocytosis of MDA-MB-231 cells (Figs. 1, 1S).
This suggested that MDA-MB-231 cancer cells might be a good
model system for evaluating the activity of the pro-resolving lipid.
In addition, we also conﬁrmed effects of RvD1 on phagocytosis of
THP-1 cells and other cells such as raw264.7 and peritoneal macro-
phages from mice (Figs. 1C, 2S).
In healthy animals and normal human subjects, HMGB1 is present at
an undetectable plasma level of – 5 ng/ml, but HMB1 increase to an
average of 25.2 and 83.7 ng/ml in survivors and non-survivors among
septic patients, respectively [12]. The plasma HMGB1 median concen-
tration on the day of admission increases to 190 ng/ml in patients
with community-acquired pneumonia [48]. Analysis of synovial ﬂuid
samples from rheumatoid arthritis patients further conﬁrmed the extra-
cellular presence of HMGB1; 14 of 15 samples had HMGB-1
concentrations of 1.8–10.4 μg/ml [49].We use 3.0 μg/mlHMGB1 accord-
ing to protocols of Liu et al., [30].
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cancer cells and gene silencing of HMGB1 restored the phagocytic
capability of MDA-MB-231 cells (Fig. 2). This original ﬁnding suggests
that HMGB1might block the action of RvD1, leading to themaintenance
of inﬂammation. In accordance with our results, HMGB1 played an im-
portant role in inﬂammation [50].
HMGB1 consists of three cysteine residues: Cys23, Cys45, and
Cys106 [51]. Especially, Cys23 and Cys45 in the A box undergo a confor-
mational change in response to oxidation stress [51]. Recombinant
HMGB1 used, was shown to induce the inﬂammatory cytokines in
THP1 macrophages (Fig. 3S). This result indicated that the HMGB1
might have been disulﬁde form [51]. Therefore, our HMGB1 was
regarded as disulﬁde form. HMGB1 suppresses phagocytosis by binding
to the RAGE. The amino acid residues responsible for RAGE binding
are 150–183 residues in HMGB1 [51]. So phagocytosis seems to be inde-
pendent of redox state of cysteine residues of HMGB1 since DTT-treated
and non-treated HMGB1s did not showed the different activities in
phagocytosis (Fig. 7S).
Exactly howHMGB1 suppresses phagocytosis is still not fully under-
stood. The effects of HMGB1 on 15-PGDH, which inactivates pro-resolving mediators such as PGE2, LxA4, RvE1, and RvD1, have not
been studied at all [18,19,23]. We demonstrated that HMGB1 induced
15-PGDH, the enzyme catalyzing the oxidation and inactivation of
RvD1 (Fig. 3) [18]. HMGB1-induced expression of 15-PGDH is also con-
ﬁrmed in other cell lines including HaCat, Jurkat, HT1080, and MCF7
cells (Fig. 4S). It is likely that HMGB1 suppresses phagocytosis induced
by RvD1 by increasing the expression and activity of 15-PGDH (Figs. 3,
5S). We also conﬁrmed the oxo-RvD1 in assay mixture of 15-PGDH
containing RvD1, NAD, and cell lysates from HMGB-1-treated MDA-
MB-231 cells (Fig. 6S).
The time course of 15-PGDH induction by phorbol 12-myristate
13-acetate (PMA) was reported in U937 cells. Maximum induction
was observed at 24–36 h following the addition of PMA [27]. 15-PGDH
decrease has been reported in lung, gastric, thyroid cancers [22–24].
Reduced expression of 15-PGDH is observed in the systemic inﬂamma-
tory response and inﬂammatory bowel disease [25,26]
To conﬁrm the involvement of 15-PGDH in phagocytosis of MDA-
MB-231 cells, we silenced the 15-PGDH gene, which increased phago-
cytic activity even without RvD1 treatment (Fig. 4C). TD23, a 15-PGDH
inhibitor, also increased phagocytosis (Fig. 4D) [39]. These results sug-
gest that 15-PGDH is a key player in phagocytosis. Therefore, inhibition
of 15-PGDHmight be useful to induce the resolution phase by inhibiting
the inactivation of LxA4, RvD1 or RvE1. It is still not clear why 15-PGDH
gene silencing or inhibitor increased phagocytosis. If we focus on the
substrate of 15-PGDH, we might explain the role of 15-PGDH in phago-
cytosis. 15-PGDH inactivated the PGE2, LxA4, RvE1, and RvD1. PGE2
impairs, whereas Lxs, and Rvs, enhances phagocytosis [40,52–54].
15-PGDH gene silencing might increase PGE2, LxA4, RvD1, and RvE1,
which are substrates of this enzyme. Interestingly, PGE2 suppresses
phagocytosis, and LxA4, RvD1, and RvE1 increase phagocytosis. So,
one possible explanation is that 15-PGDH-gene-silencing-induced
increases of phagocytosis are furthered by increased amounts of LxA4,
RvD1, and RvE1. Interestingly, RvE1 is a stronger inducer of phagocyto-
sis than RvD1. Thus, it is possible that 15-PGDH-gene-silencing-induced
increases of LxA4, RvD1, and RvE1 might evoke phagocytosis. However,
these speculations need to be proven by experimentation. To this end,
we are now, as part of a new project, analyzing metabolites under the
15-PGDH gene silencing condition.
In a study by Murakami et al., they found that serum HMGB1 levels
were markedly elevated 5 h after the LPS/N-galactosamine-challenge
in mice, and it were signiﬁcantly reduced by RvD1 [55]. Contrastingly,
in our results, HMGB1 suppressed the RvD1-induced phagocytosis by
enhancing expression of 15-PGDH, which inactivates RvD1 [18]. So,
these two results reﬂect the fact that in the course of inﬂammation, ei-
ther ongoing inﬂammation or resolution might be determined by com-
bat between HMGB1 and Rvs such as RvD1.
In summary, HMGB1 suppresses RvD1-induced phagocytosis via the
expression of 15-PGDH. These mechanisms might explain how HMGB1
maintains the inﬂammatory phase, and demonstrates that 15-PGDH
might be an important target for inducing the resolution of inﬂammation.
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